543 related articles for article (PubMed ID: 31304648)
21. Imaging spinal cord atrophy in progressive myelopathies: HTLV-I-associated neurological disease (HAM/TSP) and multiple sclerosis (MS).
Azodi S; Nair G; Enose-Akahata Y; Charlip E; Vellucci A; Cortese I; Dwyer J; Billioux BJ; Thomas C; Ohayon J; Reich DS; Jacobson S
Ann Neurol; 2017 Nov; 82(5):719-728. PubMed ID: 29024167
[TBL] [Abstract][Full Text] [Related]
22. Identification and measurement of cervical spinal cord atrophy in neuromyelitis optica spectrum disorders (NMOSD) and correlation with clinical characteristics and cervical spinal cord MRI data.
Lersy F; Noblet V; Willaume T; Collongues N; Kremer L; Fleury M; de Seze J; Kremer S
Rev Neurol (Paris); 2021; 177(1-2):85-92. PubMed ID: 32753321
[TBL] [Abstract][Full Text] [Related]
23. Multicentric clinical and epidemiological comparison of neuromyelitis optica spectrum disorder with multiple sclerosis from India.
Gupta S; Rehani V; Acharya R; Purohit P; Anadure R; Ahmad F; Soni R; Gupta A; Hiremath R
Mult Scler Relat Disord; 2021 Jan; 47():102616. PubMed ID: 33166808
[TBL] [Abstract][Full Text] [Related]
24. Spinal cord atrophy in multiple sclerosis and relationship with disability across clinical phenotypes.
Bernitsas E; Bao F; Seraji-Bozorgzad N; Chorostecki J; Santiago C; Tselis A; Caon C; Zak I; Millis S; Khan O
Mult Scler Relat Disord; 2015 Jan; 4(1):47-51. PubMed ID: 25787052
[TBL] [Abstract][Full Text] [Related]
25. Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis.
Masuda H; Mori M; Uzawa A; Uchida T; Ohtani R; Kuwabara S
PLoS One; 2020; 15(4):e0224419. PubMed ID: 32251416
[TBL] [Abstract][Full Text] [Related]
26. Brain and spinal MRI features distinguishing MS from different AQP4 antibody serostatus NMOSD at disease onset in a cohort of Latin American patients.
Carnero Contentti E; Marques VD; Soto de Castillo I; Tkachuk V; Barreira AA; Caride A; Castillo MC; Cristiano E; de Aquino Cruz C; Braga Diégues Serva G; Santos ACD; Labarca R; Lavigne Moreira C; López PA; Miguez J; Molina O; Pettinicchi JP; Rojas JI
Mult Scler; 2020 Jul; 26(8):945-954. PubMed ID: 31124748
[TBL] [Abstract][Full Text] [Related]
27. Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population.
Silveira F; Pappolla A; Sánchez F; Marques VD; de Castillo IS; Tkachuk V; Caride A; Castillo MC; Cristiano E; Cruz CA; Diégues Serva GB; Dos Santos AC; Moreira CL; López PA; Patrucco L; Molina O; Pettinicchi JP; Carnero Contentti E; Rojas JI
Mult Scler Relat Disord; 2020 Jul; 42():102049. PubMed ID: 32251869
[TBL] [Abstract][Full Text] [Related]
28. The Neutrophil-to-Lymphocyte Ratio and the Monocyte-to-Lymphocyte Ratio Predict Expanded Disability Status Scale Score at One Year in Pediatric Neuromyelitis Optica Spectrum Disorder but not in Multiple Sclerosis.
Devlin L; Gombolay G
Pediatr Neurol; 2023 Jun; 143():84-88. PubMed ID: 37044044
[TBL] [Abstract][Full Text] [Related]
29. Spinal cord atrophy in anterior-posterior direction reflects impairment in multiple sclerosis.
Lundell H; Svolgaard O; Dogonowski AM; Romme Christensen J; Selleberg F; Soelberg Sørensen P; Blinkenberg M; Siebner HR; Garde E
Acta Neurol Scand; 2017 Oct; 136(4):330-337. PubMed ID: 28070886
[TBL] [Abstract][Full Text] [Related]
30. Quantitative Magnetic Resonance Imaging Analysis of Early Markers of Upper Cervical Cord Atrophy in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.
Adibi I; Najafi A; Merajifar F; Ramezani N; Nouri H; Jalilvand N; Ashtari F; Vard A; Shaygannejad V
Mult Scler Int; 2021; 2021():9917582. PubMed ID: 34306756
[TBL] [Abstract][Full Text] [Related]
31. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
[TBL] [Abstract][Full Text] [Related]
32. Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
Masuda H; Mori M; Hirano S; Uzawa A; Uchida T; Muto M; Ohtani R; Aoki R; Kuwabara S
J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):32-40. PubMed ID: 34362853
[TBL] [Abstract][Full Text] [Related]
33. Neuromyelitis optica spectrum disorder mimicking multiple sclerosis.
van Rooij LC; Wattjes MP; de Jong BA; van Oosten BW
Mult Scler Relat Disord; 2017 Oct; 17():54-56. PubMed ID: 29055475
[TBL] [Abstract][Full Text] [Related]
34. Expression and Clinical Correlation Analysis Between Repulsive Guidance Molecule a and Neuromyelitis Optica Spectrum Disorders.
Tang J; Zeng X; Yang J; Zhang L; Li H; Chen R; Tang S; Luo Y; Qin X; Feng J
Front Immunol; 2022; 13():766099. PubMed ID: 35185873
[TBL] [Abstract][Full Text] [Related]
35. Anti-thyroid antibodies and thyroid function in neuromyelitis optica spectrum disorders.
Wang X; Yi H; Liu J; Li M; Mao ZF; Xu L; Peng FH
J Neurol Sci; 2016 Jul; 366():3-7. PubMed ID: 27288767
[TBL] [Abstract][Full Text] [Related]
36. A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis.
Outteryck O; Majed B; Defoort-Dhellemmes S; Vermersch P; Zéphir H
Mult Scler; 2015 Dec; 21(14):1781-93. PubMed ID: 25828758
[TBL] [Abstract][Full Text] [Related]
37. Spinal cord gray matter atrophy correlates with multiple sclerosis disability.
Schlaeger R; Papinutto N; Panara V; Bevan C; Lobach IV; Bucci M; Caverzasi E; Gelfand JM; Green AJ; Jordan KM; Stern WA; von Büdingen HC; Waubant E; Zhu AH; Goodin DS; Cree BA; Hauser SL; Henry RG
Ann Neurol; 2014 Oct; 76(4):568-80. PubMed ID: 25087920
[TBL] [Abstract][Full Text] [Related]
38. Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis.
Müller J; Sinnecker T; Wendebourg MJ; Schläger R; Kuhle J; Schädelin S; Benkert P; Derfuss T; Cattin P; Jud C; Spiess F; Amann M; Lincke T; Barakovic M; Cagol A; Tsagkas C; Parmar K; Pröbstel AK; Reimann S; Asseyer S; Duchow A; Brandt A; Ruprecht K; Hadjikhani N; Fukumoto S; Watanabe M; Masaki K; Matsushita T; Isobe N; Kira JI; Kappos L; Würfel J; Granziera C; Paul F; Yaldizli Ö
Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35217580
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of conventional MRI parameters in first spinal attacks of neuromyelitis optica spectrum disorder.
Bonnan M; Debeugny S; Mejdoubi M; Cabre P
Mult Scler; 2020 Apr; 26(4):468-475. PubMed ID: 30843448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
